Baylor University Medical Center at Dallas (Baylor Dallas) is now home to North Texas’ largest outpatient cancer center. The new Baylor Charles A. Sammons Cancer Center at Dallas opens to the public Saturday, March 26. The 467,000 square-foot facility marks a new era in cancer care for the Dallas-Fort Worth Metroplex and beyond by offering comprehensive services for cancer patients from initial diagnosis through post-recovery. Baylor Dallas, already the leading cancer care provider in North Texas in terms of patients treated and according to Consumer Choice data, now brings together multiple phases of cancer care under one roof.
To view Multimedia news Release, go to http://multivu.prnewswire.com/mnr/baylorhealth/47429/
InSightec Ltd, the leader in magnetic resonance imaging (MRI)-guided Focused Ultrasound therapy, announced that the U.S. Food and Drug Administration (FDA) has approved ExAblate® MRI-guided focused ultrasound as a therapy to treat pain from bone metastases in patients who do not respond or cannot undergo radiation treatment for their pain. This is the second FDA approval for ExAblate, which has been used widely since it was approved in 2004 as a non-invasive, outpatient, therapy for uterine fibroids.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56632-insightec-fda-approves-exablate
The Children’s Hospital of Philadelphia today announced the largest charitable donation in its history: a landmark $50 million gift from the Buerger family toward the construction of a new state-of-the-art outpatient facility. Currently under construction on the Hospital’s Main Campus in West Philadelphia, the building will be named the Buerger Center for Advanced Pediatric Care.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62177-children-s-hospital-of-philadelphia-buerger-center-advanced-pediatric-care
In response to the growing need for quality healthcare in Chicago, Northwestern Medicine is proud to announce the opening of a new, one-million square foot outpatient pavilion at 259 E. Erie St. The new pavilion opened on Oct. 13 in the heart of Northwestern Medicine’s downtown medical campus, home to Northwestern Memorial Hospital and Northwestern University Feinberg School of Medicine.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7049451-northwestern-medicine-to-open-259-east-erie-patient-pavilion-in-october/
Following FDA approval of the AspireSR® generator for the VNS Therapy® system in June 2015, more than a thousand patients with drug-resistant epilepsy across the United States have received this new treatment option. Many of these patients are experiencing benefits which have positively impacted their lives – and are sharing their stories during Epilepsy Awareness Month with the hope of encouraging others to seek new treatments for drug-resistant epilepsy. Numerous hospitals nationwide have begun providing the AspireSR device to patients with drug-resistant epilepsy – a condition that affects as many as one-third of people with epilepsy, causing them to have seizures in spite of treatment with antiepileptic medications.
The VNS Therapy system is a minimally invasive option in which a medical device is placed under the skin in the upper chest area during an outpatient procedure. The device sends mild electrical pulses through the vagus nerve to areas of the brain known to be associated with seizures. The new AspireSR generator takes the VNS Therapy technology a step further – detecting relative heart-rate increases that are often associated with seizures in people with epilepsy and providing responsive stimulation in an attempt to stop and shorten seizures and improve recovery.
To view the multimedia release go to:
http://www.multivu.com/players/English/7651751-livanova-aspiresr-treatment/
Cancer Treatment Centers of America® (CTCA), a national network of comprehensive cancer care hospitals and outpatient care centers, and Foundation Medicine, a leading molecular insights company that recently received FDA approval for its FoundationOne CDx™ genomic test, today announced the launch of a collaborative educational campaign designed to heighten awareness of the promise of precision medicine and the role that advanced genomic testing plays in helping identify treatments best suited for individual patients.
To view the multimedia release go to:
https://www.multivu.com/players/English/8295651-cancer-treatment-centers-of-america-foundation-medicine-precision-cancer-treatment/
